Patents by Inventor Adnan M. M. Mjalli

Adnan M. M. Mjalli has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Tricyclic compounds as modulators of TNF-? synthesis
    Patent number: 7964608
    Abstract: The present invention relates to chemical compounds of Formula (I) are as herein defined, pharmaceutical compositions, and methods of use in the treatment of conditions or disorders mediated by TNF-alpha or by PDE4, including but not limited to rheumatoid arthritis.
    Type: Grant
    Filed: January 23, 2009
    Date of Patent: June 21, 2011
    Assignee: High Point Pharmaceuticals, LLC
    Inventors: Adnan M. M. Mjalli, Bapu Gaddam, Dharma Rao Polisetti, Matthew Kostura, Mustafa Guzel
  • Rage Fusion Proteins And Methods Of Use
    Publication number: 20110124102
    Abstract: Disclosed are RAGE fusion proteins comprising RAGE polypeptide sequences linked to a second, non-RAGE polypeptide. The RAGE fusion protein may utilize a RAGE polypeptide domain comprising a RAGE ligand binding site and an interdomain linker directly linked to an immunoglobulin CH2 domain. Such fusion proteins may provide specific, high affinity binding to RAGE ligands. Also disclosed is the use of the RAGE fusion proteins as therapeutics for RAGE-mediated pathologies.
    Type: Application
    Filed: January 7, 2011
    Publication date: May 26, 2011
    Inventors: Adnan M.M. Mjalli, Ye Edward Tian, Jeffrey C. Webster, Robert Rothlein
  • Immunoglobulin Fusion Proteins and Methods of Making
    Publication number: 20110110945
    Abstract: Disclosed are immunoglobulin fusion proteins and methods of making such proteins. In certain embodiments, the fusion protein may include a non-immunoglobulin polypeptide linked to an immunoglobulin polypeptide. In certain embodiments, the non-immunoglobulin polypeptide may comprise a region that replaces an immunoglobulin Fc hinge region, but that allows for correct assembly of the immunoglobulin chains.
    Type: Application
    Filed: October 6, 2010
    Publication date: May 12, 2011
    Applicant: TransTech Pharma, Inc.
    Inventors: Adnan M.M. Mjalli, Ye Edward Tian, Jeffrey C. Webster, Robert Rothlein
  • Substituted Azole Derivatives, Compositions, and Methods of Use
    Publication number: 20110092553
    Abstract: The present invention provides azole derivatives of Formula (I), methods of their preparation, pharmaceutical compositions comprising the compounds of Formula (I), and their use in treating human or animal disorders. The compounds of the invention can be useful as inhibitors of protein tyrosine phosphatases and thus can be useful for the management, treatment, control, or the adjunct treatment of diseases mediated by PTPase activity. Such diseases include Type I diabetes and Type II diabetes.
    Type: Application
    Filed: November 19, 2010
    Publication date: April 21, 2011
    Applicant: TransTech Pharma, Inc.
    Inventors: Adnan M.M. Mjalli, Dharma R. Polisetti, Govindan Subramanian, James C. Quada, JR., Murty N. Arimilli, Ravindra R. Yarragunta, Robert C. Andrews, Rongyuan Xie
  • N-HETEROARYL INDOLE CARBOXAMIDES AND ANALOGUES THEREOF, FOR USE AS GLUCOKINASE ACTIVATORS IN THE TREATMENT OF DIABETES
    Publication number: 20110082144
    Abstract: This invention relates to compounds that are activators of glucokinase and thus may be useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial. The compounds are of the general formula (I) wherein A and B are further defined in the application.
    Type: Application
    Filed: September 30, 2010
    Publication date: April 7, 2011
    Applicant: TransTech Pharma, Inc.
    Inventors: Jesper F. Lau, Per Vedsø, János Tibor Kodra, Anthony Murray, Lone Jeppesen, Michael Ankersen, Govindan Subramanian, Adnan M. M. Mjalli, Robert Carl Andrews, Dharma Rao Polisetti, Daniel Peter Christen
  • Substituted Azole Derivatives as Therapeutic Agents
    Publication number: 20110077399
    Abstract: This invention provides azoles which may be useful as inhibitors of protein tyrosine phosphatases (PTPases). The present invention provides compounds of Formula (I), methods of their preparation, pharmaceutical compositions comprising the compounds and their use in treating human or animal disorders. The compounds of the invention may be useful as inhibitors of protein tyrosine phosphatases and thus can be useful for the management, treatment, control and adjunct treatment of diseases mediated by PTPase activity. Such diseases include Type I diabetes, Type II diabetes.
    Type: Application
    Filed: December 1, 2010
    Publication date: March 31, 2011
    Applicant: TRANSTECH PHARMA, INC.
    Inventors: Adnan M. M. Mjalli, Robert C. Andrews, Ravindra R. Yarragunta, Rongyuan Xie, Govindan Subramanian, James C. Quada, JR., Murty N. Arimilli, Dharma R. Polisetti
  • Benzazole Derivatives, Compositions, and Methods of Use as B-Secretase Inhibitors
    Publication number: 20110065713
    Abstract: The present invention is directed to benzazole compounds that inhibit ?-site amyloid precursor protein-cleaving enzyme (BACE) and that may be useful in the treatment or prevention of diseases in which BACE is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which BACE is involved.
    Type: Application
    Filed: November 19, 2010
    Publication date: March 17, 2011
    Applicant: High Point Pharmaceuticals, LLC
    Inventors: Adnan M.M. Mjalli, David Jones, Devi Reddy Gohimmukkula, Guoxiang Huang, Jeff Zhu, Mohan Rao, Robert C. Andrews, Tan Ren
  • Oxadiazoanthracene compounds for the treatment of diabetes
    Patent number: 7906507
    Abstract: The present invention provides methods of use of oxadiazoanthracene derivatives of the formula (I) and pharmaceutically acceptable salts thereof, wherein A, B, C, R, R1, R2, R3, R4 and R5 are as herein described, and wherein said methods of use include uses for the treatment and/or prevention of disorders and diseases, such as diabetes.
    Type: Grant
    Filed: August 3, 2010
    Date of Patent: March 15, 2011
    Assignee: TransTech Pharma, Inc.
    Inventors: Adnan M. M. Mjalli, Dharma Rao Polisetti, Thomas Scott Yokum, Kalpathy Santhosh, Mustafa Guzel, Christopher Behme, Stephen Thomas Davis
  • Rage fusion proteins
    Patent number: 7901688
    Abstract: Disclosed are RAGE fusion proteins comprising RAGE polypeptide sequences linked to a second, non-RAGE polypeptide. The RAGE fusion protein may utilize a RAGE polypeptide domain comprising a RAGE ligand binding site and an interdomain linker directly linked to an immunoglobulin CH2 domain. Such fusion proteins may provide specific, high affinity binding to RAGE ligands. Also disclosed is the use of the RAGE fusion proteins as therapeutics for RAGE-mediated pathologies.
    Type: Grant
    Filed: August 3, 2005
    Date of Patent: March 8, 2011
    Assignee: Transtech Pharma, Inc.
    Inventors: Adnan M. M. Mjalli, Ye Edward Tian, Jeffrey C. Webster, Robert Rothlein
  • Aryl carbonyl derivatives as therapeutic agents
    Patent number: 7897628
    Abstract: This invention relates to aryl carbonyl derivatives which are activators of glucokinase which may be useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial.
    Type: Grant
    Filed: October 31, 2007
    Date of Patent: March 1, 2011
    Assignee: Novo Nordisk A/S
    Inventors: Dharma Rao Polisetti, Janos Tibor Kodra, Jesper Lau, Paw Bloch, Maria Carmen Valcarce Lopez, Niels Blume, Mustafa Guzel, Kalpathy Chidambareswaran Santhosh, Adnan M.M. Mjalli, Robert Carl Andrews, Govindan Subramanian, Michael Ankersen, Per Vedso, Anthony Murray, Lone Jeppesen
  • Benzazole derivatives, compositions, and methods of use as ?-secretase inhibitors
    Patent number: 7893267
    Abstract: The present invention is directed to benzazole compounds that inhibit ?-site amyloid precursor protein-cleaving enzyme (BACE) and that may be useful in the treatment or prevention of diseases in which BACE is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which BACE is involved.
    Type: Grant
    Filed: March 14, 2006
    Date of Patent: February 22, 2011
    Assignee: High Point Pharmaceuticals, LLC
    Inventors: Adnan M. M. Mjalli, David Jones, Devi Reddy Gohimmukkula, Guoxiang Huang, Jeff Zhu, Mohan Rao, Robert C. Andrews, Tan Ren
  • Probes, Systems, and Methods for Drug Discovery
    Publication number: 20110039714
    Abstract: Aspects of the present invention include probes, methods, systems that have stand alone utility and may comprise features of a drug discovery system or method. The present invention also includes pharmaceutical compositions. In more detail, the present invention provides molecular probes and methods for producing molecular probes. The present invention provides also provides systems and methods for new drug discovery. An embodiment of the present invention utilizes sets of probes of the present invention and a new approach to computational chemistry in a drug discovery method having increased focus in comparison to heretofore utilized combinatorial chemistry. The present invention also provides computer software and hardware tools useful in drug discovery systems.
    Type: Application
    Filed: October 8, 2010
    Publication date: February 17, 2011
    Inventors: Adnan M. M. Mjalli, Chris Wysong, Jerome Baudry, Thomas Scott Yokum, Rob Andrews, William K. Banner
  • OXADIAZOANTHRACENE COMPOUNDS FOR THE TREATMENT OF DIABETES
    Publication number: 20110039837
    Abstract: The present invention provides methods of use of oxadiazoanthracene derivatives of the formula (I) and pharmaceutically acceptable salts thereof, wherein A, B, C, R, R1, R2, R3, R4 and R5 are as herein described, and wherein said methods of use include uses for the treatment and/or prevention of disorders and diseases, such as diabetes.
    Type: Application
    Filed: August 3, 2010
    Publication date: February 17, 2011
    Applicant: TRANSTECH PHARMA, INC.
    Inventors: Adnan M.M. Mjalli, Dharma Rao Polisetti, Thomas Scott Yokum, Kalpathy Santhosh, Mustafa Guzel, Christopher Behme, Stephen Thomas Davis
  • OXADIAZOANTHRACENE COMPOUNDS FOR THE TREATMENT OF DIABETES
    Publication number: 20100324033
    Abstract: The present invention provides methods of use of oxadiazoanthracene derivatives of the formula (I) and pharmaceutically acceptable salts thereof, wherein A, B, C, R, R1, R2, R3, R4 and R5 are as herein described, and wherein said methods of use include uses for the treatment and/or prevention of disorders and diseases, such as diabetes.
    Type: Application
    Filed: August 31, 2010
    Publication date: December 23, 2010
    Applicant: TRANSTECH PHARMA, INC.
    Inventors: Adnan M.M. Mjalli, Dharma Rao Polisetti, Thomas Scott Yokum, Kalpathy Santhosh, Mustafa Guzel, Christopher Behme, Stephen Thomas Davis
  • Carboxamide Derivatives As Therapeutic Agents
    Publication number: 20100286197
    Abstract: This invention provides certain compounds, methods of their preparation, pharmaceutical compositions comprising the compounds, and their use in treating human or animal disorders. The compounds of the invention are useful as modulators of the interaction between the receptor for advanced glycated end products (RAGE) and its ligands, such as advanced glycated end products (AGEs), S100/calgranulin/EN-RAGE, ?-amyloid and amphoterin, and for the management, treatment, control, or as an adjunct treatment for diseases in humans caused by RAGE. Such diseases or disease states include acute and chronic inflammation, the development of diabetic late complications such as increased vascular permeability, nephropathy, atherosclerosis, and retinopathy, the development of Alzheimer's disease, erectile dysfunction, and tumor invasion and metastasis.
    Type: Application
    Filed: July 20, 2010
    Publication date: November 11, 2010
    Inventors: Adnan M.M. Mjalli, Rober C. Andrews, Ramosh Gopalaswamy, Chris Wysong
  • Substituted heteroaryl derivatives, compositions, and methods of use
    Patent number: 7820704
    Abstract: The present invention provides substituted heteroaryl derivatives of Formula (I), methods of their preparation, pharmaceutical compositions comprising the compounds of Formula (I), and methods of use in treating human or animal disorders. The compounds of the invention can be useful as inhibitors of action of AgRP on a melanocortin receptor and thus can be useful for the management, treatment, control, or the adjunct treatment of diseases which may be responsive to the modulation of melanocortin receptors including obesity-related disorders.
    Type: Grant
    Filed: April 20, 2005
    Date of Patent: October 26, 2010
    Assignee: TransTech Pharma, Inc.
    Inventors: Adnan M. M. Mjalli, Bapu R. Gaddam, Ghassan Qabaja, Govindan Subramanian, Jeff Zhu, John Dankwardt, Murty N. Arimilli, Robert C. Andrews, Samuel Victory, Ye E. Tian
  • Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors
    Patent number: 7820821
    Abstract: The present invention relates to compounds and methods from the treatment of cancer. The invention provides compounds that inhibit Aurora kinase, pharmaceutical compositions comprising compounds that inhibit Aurora kinase, and methods for the treatment of cancer using the compounds of the presentation invention or pharmaceutical compositions comprising compounds of the present invention.
    Type: Grant
    Filed: February 9, 2007
    Date of Patent: October 26, 2010
    Assignee: TransTech Pharma, Inc.
    Inventors: Adnan M. M. Mjalli, Brian S. Grella, Govindan Subramanian, Murty N. Arimilli, Ramesh Gopalaswamy, Robert C. Andrews, Stephen Davis, Xiaochuan Guo, Jeff Zhu
  • N-heteroaryl indole carboxamides and analogues thereof, for use as glucokinase activators in the treatment of diabetes
    Patent number: 7812043
    Abstract: This invention relates to compounds that are activators of glucokinase and thus may be useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial. The compounds are of the general formula (I) wherein A and B are further defined in the application.
    Type: Grant
    Filed: May 24, 2006
    Date of Patent: October 12, 2010
    Assignee: TransTech Pharma, Inc.
    Inventors: Jesper F Lau, Per Vedsø, János Tibor Kodra, Anthony Murray, Lone Jeppesen, Michael Ankersen, Govindan Subramanian, Adnan M. M. Mjalli, Robert Carl Andrews, Dharma Rao Polisetti, Daniel Peter Christen
  • Azole derivatives and fused bicyclic azole derivatives as therapeutic agents
    Publication number: 20100256119
    Abstract: This invention provides certain compounds, methods of their preparation, pharmaceutical compositions comprising the compounds, and their use in treating human or animal disorders. The compounds of the invention are useful as modulators of the interaction between the receptor for advanced glycated end products (RAGE) and its ligands, such as advanced glycated end products (AGEs), S100/calgranulin/EN-RAGE, ?-amyloid and amphoterin, and for the management, treatment, control, or as an adjunct treatment for diseases in humans caused by RAGE. Such diseases or disease states include acute and chronic inflammation, the development of diabetic late complications such as increased vascular permeability, nephrdpathy, atherosclerosis, and retinopathy, the development of Alzheimer's disease, erectile dysfunction, and tumor invasion and metastasis.
    Type: Application
    Filed: May 5, 2010
    Publication date: October 7, 2010
    Inventors: Adnan M.M. Mjalli, Robert C. Andrews, Ramesh Gopalaswamy, Anitha Hari, Kwasi S. Avor, Ghassan Qabaja, Xiao-Chuan Guo, Suparna Gupta, David R. Jones, Xin Chen
  • Oxadiazoanthracene compounds for the treatment of diabetes
    Patent number: 7790714
    Abstract: The present invention provides methods of use of oxadiazoanthracene derivatives of the formula (I) and pharmaceutically acceptable salts thereof, wherein A, B, C, R, R1, R2, R3, R4 and R5 are as herein described, and wherein said methods of use include uses for the treatment and/or prevention of disorders and diseases, such as diabetes.
    Type: Grant
    Filed: April 13, 2010
    Date of Patent: September 7, 2010
    Assignee: TransTech Pharma, Inc.
    Inventors: Adnan M.M. Mjalli, Dharma Rao Polisetti, Thomas Scott Yokum, Kalpathy Santhosh, Mustafa Guzel, Christopher Behme, Stephen Thomas Davis